Mr. Thomas Braun reports

VERISANTE TECHNOLOGY, INC. ANNOUNCES EXCLUSIVE DISTRIBUTION AGREEMENT WITH LASERWELT BERLIN FOR GERMANY, AUSTRIA AND LIECHTENSTEIN

Verisante Technology Inc. has entered into an exclusive agreement with Laserwelt to distribute Verisante Aura in Germany, Austria and Liechtenstein.

"Laserwelt is one of the most successful independent distributors of medical devices in German-speaking countries," said Thomas Braun, president and chief executive officer of Verisante. "Germany is one of the largest markets in Europe for dermatological and skin care devices. Our partnership with Laserwelt will provide a strong foundation in this important region. Laserwelt will distribute Aura and also support technical training and servicing in Germany, Austria and Liechtenstein."

Laserwelt has a showroom in downtown Berlin and currently distributes the world's top dermatological brands of medical devices for skin care treatments, in addition to other devices for use in dermatological practices for a variety of other medical applications. Aura is a complementary addition to the company's existing product line.

"Germany is the only country in the world that has a national skin cancer screening program for persons over 35 years of age," said Michael Landsberg, owner and president of Laserwelt. "Given that Aura's clinical study results show the device can quickly and accurately assist in skin cancer diagnosis, we are confident of widespread market adoption."

The European medical device market is the second largest in the world, worth over $78-billion and representing 30 per cent of the world market -- second only to the United States. Last year, Aura received the Conformite Europeenne (CE) Mark approval. CE Mark is recognized by all the 27 member states of the European Union, including Germany, which has a total population of over 81 million people, and over 5,000 dermatologists serving the country.

In Germany the incidence of skin cancers has tripled since 1980 and is about 20 per cent higher than the rest of Europe, with melanoma accounting for 2,217 deaths each year. Germany also offers a reimbursement under its state health insurance which covers skin cancer screenings every two years for people age 35 and older.

Verisante Aura is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

We seek Safe Harbor.